In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
|Videos|June 27, 2021
Dr. Eure on BPH medications and increased risk of heart failure
Author(s)Urology Times staff
Advertisement
Gregg Eure, MD, FACS, Urology of Virginia, discusses the increased of heart failure associated with medications for the treatment of patients with benign prostatic hyperplasia (BPH).
Advertisement
Related to this article
Cameron C. Jones, MD, discusses patient selection for Aquablation, including prostate size, anatomy, and factors that may favor alternative BPH procedures.
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
FDA updates in urology: September 2026
3
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5